Basking Biosciences

Basking Biosciences is a clinical-stage biopharmaceutical company in Research Triangle, North Carolina (with operations in Mitchelton, Queensland, Australia) developing novel therapies for life-threatening blood clots. Its lead program BB-031 is an investigational RNA aptamer that targets von Willebrand Factor (vWF) to deliver a rapid-onset, targeted, and reversible thrombolytic for acute ischemic stroke, paired with BB-025, a direct-acting reversal agent designed to rapidly neutralize BB-031. The company is running the RAISE Phase 2 clinical trial and is backed by Insight Partners. Surfaced as a VC portfolio company and added to the API Evangelist network; the company publishes no public developer API, SDK, or documentation surface, so this profile carries company identity only.

Basking Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotech Therapeutics, Biopharmaceutical, Clinical Stage, and Stroke.

Basking Biosciences’ developer surface includes engineering blog and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Biotech Therapeutics Biopharmaceutical Clinical Stage StrokeThrombosisDrug Development Life Sciences

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 10.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/basking-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 4

The organization behind the API

Website

Website

About

About

Blog

Blog

LinkedIn

Source (apis.yml)

aid: basking-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/basking-biosciences.png
name: Basking Biosciences
description: Basking Biosciences is a clinical-stage biopharmaceutical company in Research Triangle, North Carolina (with
  operations in Mitchelton, Queensland, Australia) developing novel therapies for life-threatening blood clots. Its lead program
  BB-031 is an investigational RNA aptamer that targets von Willebrand Factor (vWF) to deliver a rapid-onset, targeted, and
  reversible thrombolytic for acute ischemic stroke, paired with BB-025, a direct-acting reversal agent designed to rapidly
  neutralize BB-031. The company is running the RAISE Phase 2 clinical trial and is backed by Insight Partners. Surfaced as
  a VC portfolio company and added to the API Evangelist network; the company publishes no public developer API, SDK, or documentation
  surface, so this profile carries company identity only.
url: https://raw.githubusercontent.com/api-evangelist/basking-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-08-10'
tags:
- Company
- Biotech Therapeutics
- Biopharmaceutical
- Clinical Stage
- Stroke
- Thrombosis
- Drug Development
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/basking-biosciences-domain-security.yml
- type: Website
  url: https://www.baskingbiosciences.com/
- type: About
  url: https://www.baskingbiosciences.com/about
- type: Blog
  url: https://www.baskingbiosciences.com/news
- type: LinkedIn
  url: https://www.linkedin.com/company/basking-biosciences-inc
- type: PrivacyPolicy
  url: https://www.baskingbiosciences.com/legal/privacy-policy
- type: TermsOfService
  url: https://www.baskingbiosciences.com/legal/terms-of-use
- type: LLMsTxt
  url: llms/basking-biosciences-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-08-10'
  status: minimal
  artifacts_added: 4
  pass: local-v1
  note: Full STEP 0b contract discovery run against every apparent host. No spec, no developer surface, no packages, no GitHub
    org. Probed absences recorded in well-known/ and packages/; domain security probed; llms.txt generated.
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Basking Biosciences is a clinical-stage biopharmaceutical company developing the RNA-aptamer thrombolytic BB-031;
    its entire web presence is a 20-URL Webflow marketing site (science, programs, publications, news releases, legal) whose
    sitemap contains no developer, docs, or API path, and api.baskingbiosciences.com does not resolve in DNS.
  evidence:
  - url: https://www.baskingbiosciences.com/sitemap.xml
    status: 200
  - url: https://www.baskingbiosciences.com/openapi.json
    status: 404
  - url: https://www.baskingbiosciences.com/developers
    status: 404
  - url: https://www.baskingbiosciences.com/.well-known/agent-card.json
    status: 404
  - url: https://pypi.org/pypi/basking-biosciences/json
    status: 404
  checked: '2026-08-10'